Medicinova

MediciNova is focusing on two near-term catalysts: top-line results for MN-001 in September 2026 and the COMBAT-ALS study (MN-166) by year-end. The company has completed COMBAT-ALS enrollment, holds $25.4 million in cash, has no debt and reported a historical annual cash burn of about $12–13 million. Management emphasizes that the next value uplift should come from clinical data, not financing; non-core programs will be funded externally to limit dilution. » Więcej na de.investing.com

MediciNova approved new employment agreements for President/CEO Dr. med. Dr. Yuichi Iwaki and CMO Dr. med. Dr. Kazuko Matsuda effective August 17, 2026, providing fixed annual salaries of $690,246 (Iwaki) and $540,143 (Matsuda) and performance-based annual bonuses (target: 55% and 40% of base salary, respectively). Both contracts replace prior arrangements, include severance payments for involuntary termination without cause and tiered, substantially higher payouts plus accelerated equity vesting for terminations related to a change of control; they also include a one-year post-contract non-solicitation clause and are governed by Delaware law. Despite 584% revenue growth last year, MediciNova remains unprofitable; analysts' price targets range from $6 to $11. » Więcej na de.investing.com

MediciNova reports that the SEANOBI-ALS study of MN-166 (Ibudilast) has reached its recruitment target of 200 patients under the Expanded Access Program. The study is funded by the National Institute of Neurological Disorders and Stroke and the NIH under the "ACT for ALS" program; final follow-ups are expected to conclude in early 2027 and trigger the start of data analysis. MN-166 is an orally active PDE4 and cytokine inhibitor with orphan and Fast Track designations, and analyst price targets for the stock range from $6 to $11, well above the current share price of $1.37. » Więcej na de.investing.com